Skip to main content
Clinical and Translational Medicine
Fig. 1 | Clinical and Translational Medicine

Fig. 1

From: Rethinking the combination treatment of fulvestrant and anastrozole for metastatic breast cancer: an integrated reanalysis of aromatase–estrogen receptor axis

Fig. 1

Prognostic analyses of CYP19A1–ESR axis in breast cancer. a–d OS, RFS, DMFS and PPS of integrated CYP19A1 and ESR1/ESR2 in breast cancer patients (n = 1402 in OS, 3951 in RFS, 1746 in DMFS, 414 in PPS respectively). e–h OS, RFS, DMFS and PPS of integrated CYP19A1 and ESR1/ESR2 in untreated breast cancer patients (n = 382 in OS, 1010 in RFS, 543 in DMFS, 137 in PPS respectively). The detailed HR and logrank p-value were individually shown as indicated in each panel, and p-value < 0.05 was considered statistically significant

Back to article page